Abstract
The annual European Respiratory Society (ERS) International Congress (held in Paris in 2018) was once again a platform for discussion of the highest-quality scientific research, cutting-edge techniques and innovative new therapies within the respiratory field. This article discusses only some of the high-quality research studies presented at this year's Congress, with a particular focus on airway diseases including asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis and cough, as presented through Assembly 5 of the ERS (Airway Diseases: Asthma and COPD). The authors establish the key take-home messages of these studies, compare their findings and place them in the context of current understanding.
Abstract
A review of the high-quality research studies presented at the 2018 #ERSCongress, with a focus on airway diseases, including asthma, COPD, bronchiectasis and cough, presented through Assembly 5 of @ERStalk http://ow.ly/tQCl30nrPMI
Footnotes
Conflict of interest: F. Schleich has nothing to disclose.
Conflict of interest: A. Bikov has nothing to disclose.
Conflict of interest: A.G. Mathioudakis reports grants and personal fees from Boehringer Ingelheim, and personal fees from GlaxoSmithKline, outside the submitted work.
Conflict of interest: M. McDonnell reports grants from the Health Research Board, Ireland, outside the submitted work.
Conflict of interest: C. Andersson has nothing to disclose.
Conflict of interest: M. Bonini has nothing to disclose.
Conflict of interest: L. Uller has nothing to disclose.
Conflict of interest: M. Idzko has nothing to disclose.
Conflict of interest: D. Singh reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Glenmark, Menarini, Mundipharma, Novartis, Pfizer, Pulmatrix, Therevance and Verona, and personal fees from Cipla and Peptinnovate, outside the submitted work.
Conflict of interest: J.L. Lopez-Campos reports personal fees and nonfinancial support from Boehringer, Grifols, Novartis, Chiesi, AstraZeneca and GSK, personal fees from Teva, Rovi, Ferrer, Bial, Esteve and Gebro Pharma, and grants, personal fees and nonfinancial support from Menarini, outside the submitted work.
Conflict of interest: A. Bossios reports personal fees and other support for consultancy from AstraZeneca, Teva and GSK, outside the submitted work.
Conflict of interest: I.M. Adcock has nothing to disclose.
Conflict of interest: O. Usmani reports grants and personal fees from AstraZeneca, Boehringer Ingelheim and Chiesi, personal fees from Aerocrine, Napp, Mundipharma, Sandoz, Prosonix, Takeda, Zentiva Cipla and Pearl Therapeutics, and grants from GlaxoSmithKline and Edmond Pharma, outside the submitted work.
Conflict of interest: A. Spanevello has nothing to disclose.
Conflict of interest: S.J. Bonvini has nothing to disclose.
- Received November 28, 2018.
- Accepted January 9, 2019.
- Copyright ©ERS 2019
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.